OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
10 feb 2010 - 07:29
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces that interim Locteron Phase IIb data have been accepted for oral and poster presentations at International Liver Congress in April
Bericht
OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO) announces today that its licensee Biolex Therapeutics (see separate Biolex press release on www.biolex.com) has been accepted to present interim results from two ongoing Phase IIb studies with Locteron® at the 45th Liver Congress on 14 -18 April 2010 in Vienna, Austria.
Simon Sturge, CEO of OctoPlus, says: “We are delighted that the interim data for Locteron have been one of few to be selected for an oral presentation at this prestigious conference. We look forward to seeing the data and believe that this is very good news for the future of Locteron."
Datum laatste update: 19 december 2025